Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline | Journal of Clinical Oncology
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 - Annals of Oncology
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort - ESMO Open
Frontiers | Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials | Oncology
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients - European Journal of Cancer
Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis
Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study | Scientific Reports
Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer
Chemo or Hormone Therapy Result in Similar Survival for Women with Breast Cancer - CancerConnect
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis - The Lancet Oncology
Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment. - Abstract - Europe PMC
PDF) Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton
First-line Durvalumab Improves Survival
Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis | Scientific Reports
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Breast cancer - The Lancet
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial - Annals of Oncology
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort - ESMO Open
Update on systemic treatment for newly diagnosed inflammatory breast cancer - ScienceDirect
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients - European Journal of Cancer
Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China - ScienceDirect
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Effects of Alkalization Therapy on Chemotherapy Outcomes in Metastatic or Recurrent Pancreatic Cancer | Anticancer Research
Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer | NEJM
Tumour Cell Secretome in Chemoresistance and Tumour Recurrence: Trends in Cancer
Adjuvant endocrine therapy is associated with improved overall survival in elderly hormone receptor-positive breast cancer patients | SpringerLink
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Previous Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination Chemotherapy | Anticancer Research
